Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: Cancer Antigen 15.3

Search for Biomarkers

Analyte:

Cancer Antigen 15.3

Platform:

Status:

Experienced Running

Biological or Clinical Significance:

CA15-3 (Cancer Antigen 15-3) is a tumor marker used to monitor certain cancers, especially breast cancer. It is found on the surface of many types of cancer cells and shed into the blood stream. It is used to monitor advanced, i.e. metastatic, cancer. Elevated CA15-3, in conjunction with alkaline phosphatase (ALP), was found to be associated with an increased chance of early recurrence in breast cancer.

CA15-3 and associated CA27.29 (aka BR27.29) are different epitopes on the same protein antigen product of the breast cancer-associated MUC1 gene. CA27.29 has enhanced sensitivity and specificity and has therefore surpassed CA15-3 as a serum tumor marker. CA27.29 is elevated in 30% of patients with low-stage disease and 60 to 70% of patients with advanced-stage breast cancer.

Both CA27.29 and CA15-3 may be elevated in patients with benign ovarian cysts, benign breast disease, and benign liver disease. Elevations may also be seen in cirrhosis, sarcoidosis and lupus.

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies